-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, SBv7cakl4aUFhY9lIih27g3oqVHazxP6oLk6pn2hvjo2K/l+k28S3NhawFqtwRDS alNZ0QC36XqbRzMVOlzWSQ== 0000912057-01-527498.txt : 20010813 0000912057-01-527498.hdr.sgml : 20010813 ACCESSION NUMBER: 0000912057-01-527498 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20010810 FILED AS OF DATE: 20010810 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VISIBLE GENETICS INC CENTRAL INDEX KEY: 0001010819 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-28550 FILM NUMBER: 1703131 BUSINESS ADDRESS: STREET 1: 700 BAY ST STREET 2: SUITE 1000 CITY: TORONTO ONTARIO CANA STATE: A6 BUSINESS PHONE: 2127025700 MAIL ADDRESS: STREET 1: 700 BAY ST STE 1000 STREET 2: TORONTO ONTARIO CANADA CITY: M5G 1Z6 6-K 1 a2056331z6-k.txt FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Issuer PURSUANT to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Filing No. 2 for the Month of August, 2001 Visible Genetics Inc. (Exact name of Registrant) 700 Bay Street, Suite 1000, Toronto ON, Canada M5G 1Z6 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F Form 20-F X Form 40-F __ --- Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes __ No X VISIBLE GENETICS INC. On March 30, 2000, we entered into an Underwriting Agreement, with FleetBoston Robertson Stephens Inc., PaineWebber Incorporated, Warburg Dillon Read LLC and Roth Capital Partners, Inc., as representatives of the several underwriters named therein. In the underwriting agreement, we agreed to make generally available to our security holders and the representatives of the underwriters an earning statement covering the twelve month period ended June 30, 2001 and satisfying the requirements of Section 11(a) of the Securities Act of 1933, as amended. We hereby submit this Form 6-K and the earning statement attached hereto as Exhibit 1, in accordance with Section 11(a) of the Securities Act of 1933, as amended and Rule 158 promulgated thereunder and in satisfaction of our obligations under the underwriting agreement. This Form 6-K may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks, uncertainties and other factors which may cause our results to differ materially from expectations. These include risks relating to the ability to obtain regulatory approval, market acceptance of genotyping and our products, delays in product development, delays in making the new Atlanta manufacturing facility operational, and other risks detailed from time to time in our SEC filings, including our most recent Annual Report on Form 20-F. These forward-looking statements speak only as of the date hereof. We disclaim any intent or obligation to update these forward-looking statements. Exhibit 1. Earning Statement SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. VISIBLE GENETICS INC. Date: August 10, 2001 By: /s/ THOMAS CLARKE ----------------- Name: Thomas Clarke Title: Chief Financial Officer EX-1 3 a2056331zex-1.txt EXHIBIT 1 Exhibit 1 Visible Genetics Inc. Consolidated Statements of Operations for 12 months ended June 30 2001 (United States Dollars) (Unaudited) Sales Products $ 13,271,407 Services 251,934 ------------ 13,523,341 ------------ Cost of sales Products 10,260,562 Services 247,784 ------------ 10,508,346 ------------ Gross margin 3,014,995 Expenses Sales, general and administrative 32,158,977 Research and development 11,030,330 Exit and termination costs 540,000 ------------ 43,729,307 ------------ Loss from operations before interest (40,714,312) Interest income 4,370,514 Interest and financing expense (12,237) ------------ Net loss for the period (36,356,035) ------------ Cumulative preferred dividends and accretion of discount attributable to preferred stock (3,381,168) ------------ Net loss attributable to common shareholders $ (39,737,203) ------------ Weighted average number of common shares outstanding 16,070,019 ------------ Basic and fully diluted loss per share $ (2.47) ------------ -----END PRIVACY-ENHANCED MESSAGE-----